4//SEC Filing
Lippis Daniel J. 4
Accession 0001225208-25-009066
CIK 0001099800other
Filed
Nov 9, 7:00 PM ET
Accepted
Nov 10, 6:06 PM ET
Size
8.8 KB
Accession
0001225208-25-009066
Insider Transaction Report
Form 4
Lippis Daniel J.
CVP, TAVR
Transactions
- Exercise/Conversion
Common Stock
2025-11-10$59.26/sh+1,020$60,442→ 23,021.91 total - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2025-11-10−1,020→ 6,114 totalExercise: $59.26From: 2020-05-08Exp: 2026-05-07→ Common Stock (1,020 underlying) - Sale
Common Stock
2025-11-10$82.55/sh−1,020$84,196→ 22,001.91 total
Footnotes (2)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025.
- [F2]This transaction was executed in multiple trades at prices ranging from $82.27 to $82.90. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Documents
Issuer
Edwards Lifesciences Corp
CIK 0001099800
Entity typeother
Related Parties
1- filerCIK 0002004380
Filing Metadata
- Form type
- 4
- Filed
- Nov 9, 7:00 PM ET
- Accepted
- Nov 10, 6:06 PM ET
- Size
- 8.8 KB